• Immunome, Inc. previously announced that the FDA accepted its New Drug Application for varegacestat, an oral once-daily gamma secretase inhibitor for adults with desmoid tumors, assigning an April 28, 2027 PDUFA target action date based on the Phase 3 RINGSIDE trial.
• The NDA rests on RINGSIDE data showing a statistically significant and clinically meaningful improvement in progression-free survival versus placebo, with a very large reduction in the risk of disease progression or death.
• Against this backdrop, we will examine how FDA acceptance of the varegacestat NDA and its strong Phase 3 profile shape Immunome’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Immunome's Investment Narrative?

To own Immunome, you have to believe that varegacestat can anchor a viable oncology franchise while the earlier antibody drug conjugate programs mature. The NDA acceptance meaningfully sharpens the story: it locks in a PDUFA decision date and upgrades varegacestat from a late‑stage asset to a defined regulatory catalyst, even if commercial timelines remain out on the horizon. In the near term, that shifts attention toward regulatory review quality, potential label scope and any partnering or financing decisions made ahead of 2027, rather than binary trial risk. At the same time, the business is still small in revenue, running sizeable losses and recently exited key Russell indices, so capital needs and trading volatility stay front and center. The new FDA milestone fits squarely into that risk‑reward tradeoff.

However, one financing and dilution risk now looms larger that investors should not ignore. Despite retreating, Immunome's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Two Simply Wall St Community fair value views span roughly US$35 to above US$180 per share, showing just how far apart private investors can be. Set that against an NDA already accepted but profitability still some distance away, and you can see why it pays to weigh several perspectives before deciding how Immunome might fit in a portfolio.

Explore 2 other fair value estimates on Immunome - why the stock might be worth just $35.77!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.